# CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

> **NCT04510051** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 18 (estimated)

## Conditions studied

- Malignant Brain Neoplasm
- Recurrent Malignant Brain Neoplasm
- Refractory Malignant Brain Neoplasm

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

## Key facts

- **NCT ID:** NCT04510051
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-04
- **Primary completion:** 2027-02-24
- **Final completion:** 2027-02-24
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510051, "CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04510051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*